相关实验视频

Updated: Sep 20, 2025

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

经FDA批准的药物库查确定了蛋白酶体抑制剂作为血管肉瘤细胞的选择性细胞毒剂

Che-Yuan Hsu^1,2, Teruki Yanagi^3,4, Kodai Miyamoto^1,2

¹Department of Dermatology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.

British journal of cancer

|May 29, 2025

概括

蛋白酶体抑制剂博尔特佐米布 (Bortezomib) 显示出作为皮肤血管肉瘤 (CAS) 的新疗法具有前途. 这项研究确定博特佐米布在降低CAS细胞生长和诱导亡方面具有有效性,在体外和体内.

科学领域:

在瘤学瘤学.
药物发现药物发现药物发现
癌症生物学癌症生物学

背景情况:

皮肤血管肉瘤 (CAS) 是一种具有不良预后和有限治疗选择的侵袭性癌症.
确定新的治疗策略对于改善高级CAS患者的治疗结果至关重要.
对CAS细胞系的基因分析揭示了潜在的治疗点.

研究的目的:

选FDA批准的药物对抗皮肤血管肉瘤的潜在疗效.
识别和验证CAS治疗的新型治疗候选药物.
研究有前途的候选药物的作用机制.

主要方法:

使用HAMON血管肉瘤细胞系对4681种FDA批准的化合物的药物选.
在体外测定包括ATP,MTT,克隆基因,DNA含量FACS和Annexin V-propidium iodide染色.
在体内研究使用免疫功能低下的小鼠异种移植模型.

主要成果:

一种蛋白酶体抑制剂的博特佐米布 (Bortezomib) 成为药物查中最有效的化合物.
博特佐米布在实验室中对CAS细胞表现出显著的抗增殖和亲产的作用.
博特佐米布在体内诱导了瘤细胞的亡,并激活了NF-κB和内质网膜应激通路.

结论:

博尔特佐米布被确定为皮肤血管肉瘤的潜在治疗候选者.
这项研究在CAS的体外和体外模型中提供了博特佐米布疗效的证据.
对于CAS治疗的博特佐米布的进一步临床研究是有必要的.

更多相关视频

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...